---
title: "Tariff clouds loom large! Barclays names the \"pressure-resistant king\" and \"disaster area\" in the US medical device industry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236335933.md"
description: "Barclays Bank analyzed the impact of the new tariff policy of the Trump administration on the medical device industry in its research report. The report pointed out that Abbott and Baxter International will be the least affected companies, while Johnson & Johnson and Medtronic will be the most affected. Among large medical technology companies, Abbott, Baxter International, Edwards Lifesciences, and Intuitive Surgical were rated as \"buy,\" while Zimmer Biomet Holdings was rated as \"sell.\" Small and mid-cap stocks such as Globus Medical, AlphaTek, and Tandem Diabetes Care are also less affected. In contrast, companies like Becton Dickinson, InMode, and Medtronic face significant tariff risks"
datetime: "2025-04-17T03:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236335933.md)
  - [en](https://longbridge.com/en/news/236335933.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236335933.md)
generator: "portal-rs"
---

# Tariff clouds loom large! Barclays names the "pressure-resistant king" and "disaster area" in the US medical device industry

According to the Zhitong Finance APP, Barclays Bank analyzed the impact of the new tariff policy of the Trump administration on the medical device industry in a research report. The report pointed out that Abbott (ABT.US) and Baxter International (BAX.US) will be among the least affected companies, while Johnson & Johnson (JNJ.US) and Medtronic (MDT.US) will be the most affected companies.

Barclays analysts stated that among large medical technology companies, Abbott, Baxter International, Edwards Lifesciences (EW.US), and Intuitive Surgical (ISRG.US) (rated "Overweight"), as well as Zimmer Biomet Holdings (ZBH.US) (rated "Underweight"), are the companies least affected by tariffs.

Similarly, according to the views of analysts from this research brokerage, in the mid-cap and small-cap stock sector, Globus Medical (GMED.US), AlphaTek (ATEC.US), and Tandem Diabetes Care (TNDM.US) seem to be minimally affected by tariffs.

Barclays analysts added that in stark contrast, several companies face significant tariff risks due to their heavy reliance on overseas production to supply products sold in the United States. These include Becton Dickinson (BDX.US), InMode (INMD.US), and Medtronic (rated "Overweight"), as well as Insulet (PODD.US), Johnson & Johnson, and Bausch + Lomb (BLCO.US) (rated "Neutral")

### Related Stocks

- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)
- [EW.US](https://longbridge.com/en/quote/EW.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [BDX.US](https://longbridge.com/en/quote/BDX.US.md)
- [INMD.US](https://longbridge.com/en/quote/INMD.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md)

## Related News & Research

- [Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?](https://longbridge.com/en/news/298140186.md)
- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Johnson & Johnson (JNJ) Could Be 24% Below Fair Value On FDA Approval News](https://longbridge.com/en/news/297955671.md)
- [Medtronic Analysts Raise Their Forecasts After Upbeat Q1 Earnings](https://longbridge.com/en/news/297780375.md)
- [Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms](https://longbridge.com/en/news/298316210.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**